T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease

T-Therapeutics closed a $133 million Series B funding round co-led by Advent Life Sciences and British Business Bank to advance clinical development of first-in-class TCR-CD3 bispecific therapies for cancer and autoimmune diseases. The company appointed Dr. Kirsty Crame as Chief Development Officer and plans to generate clinical proof-of-concept data for two lead programmes leveraging its proprietary OpTiMus platform.